Aims: Quantitative flow ratio (QFR) based on three-dimensional quantitative coronary angiography (3D-QCA) is a novel method to assess physiological functionality after treatment with stents. The current study aimed to evaluate the difference in physiological functionality nine months after implantation of a bioresorbable polymer-based sirolimus-eluting stent with an electrografting base layer (BuMA Supreme: B-SES) versus a durable polymer-based zotarolimus-eluting stent (Resolute: R-ZES).
Introduction
Angiographic late lumen loss (LLL) is considered a reliable discriminator to differentiate the performances of various coronary devices such as balloons, stents and bioresorbable scaffolds [1] [2] [3] .
However, in the current drug-eluting stent (DES) era, new devices within a very low LLL range have been compared which might have low probabilities of restenotic events, even if there is a statistically significant difference in LLL between the two devices 4, 5 . The clinical significance of comparing devices with very low LLL is debatable.
Fractional flow reserve (FFR) has been considered an accurate diagnostic tool due to its capacity to overcome the limitations of angiography in assessing the functional severity of coronary stenosis 6 . An increasing body of evidence supports the safety and efficacy of therapeutic decisions based on FFR in multiple clinical and anatomical settings [7] [8] [9] . Quantitative flow ratio (QFR) is a novel approach enabling rapid computation of FFR pullbacks from three-dimensional quantitative coronary angiography (3D-QCA) without using a pressure wire [10] [11] [12] [13] . A QFR ≤0.80 with and without hyperaemic computed flow (adenosine-flow QFR and contrastflow QFR) was reported to have favourable diagnostic accuracy in identifying a wire-derived FFR of ≤0.80 10 .
The PIONEER trial was a randomised trial which compared the biodegradable polymer-based cobalt-chromium (CoCr) platform sirolimus-eluting BuMA™ Supreme (SINOMED, Tianjin, China) stent with an electrografting base layer (B-SES) with the durable polymer-coated zotarolimus-eluting Resolute™ stent (R-ZES) (Medtronic, Minneapolis, MN, USA) and aimed to demonstrate the non-inferiority of the B-SES to the R-ZES in terms of nine-month angiographic in-stent LLL. In the current trial, the B-SES did not meet the primary endpoint of non-inferiority 14 .
Although the B-SES was significantly inferior to the R-ZES in terms of in-stent LLL (0.29±0.34 mm vs. 0.14±0.37 mm, p inferiority =0.004), the incidence of device-oriented cardiovascular events (DoCE) at 12 months was not different between the groups (4.9% vs. 5.7% p=1.00). The in-stent binary restenosis rate of the B-SES at nine months was also comparable to the R-ZES (3.3% vs. 4.4%, p=1.00). It was questionable whether statistically different LLL values within a low range impact on the functionality of the restenotic stents. The functional significance of different LLL between the B-SES and R-ZES remained to be investigated.
In the current study, we evaluated the physiological functionality of the LLL in both stents with QFR analysis.
Methods

STUDY DESIGN AND POPULATION
The current study was a post hoc substudy of the PIONEER trial comparing the B-SES with the R-ZES in patients with coronary artery disease to demonstrate non-inferiority of the B-SES to the R-ZES in terms of nine-month angiographic in-stent LLL. The details of the protocol and the main results of the trial have already been reported elsewhere 14 . The inclusion and exclusion criteria are described in the Supplementary Appendix.
CORONARY ANGIOGRAPHY
In the PIONEER trial, coronary angiography was repeated at nine-month follow-up. All angiography was preceded by an intracoronary injection of isosorbide dinitrate or nitroglycerine. According to the protocol, target lesions were recorded with at least two projections separated by more than 30° to obtain proper LLL in matched angiographic views, from which the 3D lumen reconstruction was derived in the current substudy. In the case of target lesion revascularisation (TLR), pre-TLR angiographic data were analysed as follow-up angiography.
2D QUANTITATIVE CORONARY ANGIOGRAPHY ANALYSIS
Off-line 2D-QCA was performed in an independent core laboratory (Cardialysis, Rotterdam, the Netherlands) with the CAAS system, version 5.11 (Pie Medical Imaging, Maastricht, the Netherlands) according to standard protocol. The following QCA parameters were calculated: minimal lumen diameter, reference vessel diameter (interpolated diameter of normal vessel), percent diameter stenosis ([1-minimum lumen diameter/reference vessel diameter]×100) and late lumen loss (difference between the post-procedure and follow-up minimal lumen diameter). Binary restenosis was defined as stenosis of 50 percent or greater in the target lesion or segment at angiographic follow-up. Measurements within the stented segment were defined as the in-stent analysis. The in-segment analysis included both the in-stent segment and the edge segments which were 5 mm segments proximal or distal to the implantation site.
QUANTITATIVE FLOW RATIO CALCULATION
Details regarding the QFR calculation method have been reported elsewhere 10, 15 . Briefly, the QFR calculation was based on the 3D-QCA reconstructed from two angiographic projections with angles ≥25° apart and volumetric flow rate calculated by using contrast bolus frame count. The 3D-QCA reconstruction and measurements were performed as described previously 16 . The rate of volumetric flow was assessed with a frame count based on the TIMI frame counting method 17 . The QFRs at pre-procedure, post-procedure and nine-month follow-up were assessed using validated software (QAngio XA 3D research edition 1.0; Medis medical imaging systems bv, Leiden, the Netherlands), which received Conformité Européenne (CE) marking certification for clinical usage in April 2017, by two experienced observers (T. Asano and Y. Katagiri). In the current study, the QFR value was computed by using projections without pharmacologically induced hyperaemia (contrast-flow QFR) for the analysis 10 .
The QFR analysis was performed at the distal point of the target vessel (vessel QFR). The distal point was situated at least distally of the last lesion as long as the lumen diameter was more than 2 mm. In the post-procedural and follow-up angiography, QFR gradient across the device (∆QFR POST and ∆QFR FU ) was also analysed (Figure 1) 18 . For the assessment of the progression of flow limitation within the device at nine months, the difference in QFR gradient across the device (∆QFR FU -∆QFR POST ) was calculated.
STATISTICAL ANALYSIS
Data are expressed as mean±SD or median and interquartile range with differences (95% confidence interval). Group means for continuous variables with normal distributions were compared using the Student's t-test. Categorical variables were compared using the Pearson's chi-square test or Fisher's exact test, as appropriate. A cubic polynomial regression analysis was performed to correlate LLL and difference in QFR gradient across the device. Statistical significance was assumed at a probability (p) value of <0.05. Statistical analyses were performed with SPSS, Version 24.0.0 (IBM Corp., Armonk, NY, USA).
Results
STUDY SUBJECTS
In the PIONEER trial, a total of 170 patients were included and randomly assigned to undergo treatment with B-SES (83 patients and 95 lesions) or R-ZES (87 patients and 101 lesions). For the QFR analysis, the lesions without two appropriate angiographic projections with angles ≥25˚ apart or the lesions without data for autocalibration were excluded ( Figure 2 ). All the lesions available for QFR analysis were also analysable by 2D-QCA analysis at each time point. Baseline demographics and procedural characteristics are separately reported in Supplementary Table 1 14 . Table 1 summarises the results of 2D-QCA analysis of the population with available QFR. In-stent LLL at nine months was 0.30±0.34 mm in the B-SES group versus 0.13±0.35 mm in the R-ZES group (p=0.004). In-stent %DS at nine months was 17.0±12.0% in the B-SES group and 15.5±11.6% in the R-ZES group (p=0.06).
2D-QCA ANALYSIS
QFR ANALYSIS
The QFR analysis results are summarised in Table 2 . The vessel QFRs at nine months were not significantly different between the Figure 5 shows the cumulative frequency distribution curves of QFR gradient across the device at nine months (∆QFR FU ) plotted with binary restenosis. 
Figure 1. The quantitative flow ratio (QFR) with QAngio XA 3D. QFR calculation was based on the 3D-QCA reconstructed from two angiographic projections with angles ≥25˚ apart and volumetric flow rate calculated by using contrast bolus frame count. QFR analysis was performed at the distal point of the target vessel (vessel QFR). QFR gradient across the device (in-stent
, y=∆QFR FU -∆QFR POST , x=in-stent LLL at nine months). The curve shows an apparent increase in difference in QFR gradient across the device (∆QFR FU -∆QFR POST ) within the range of low value LLL (<0.50 mm), where the LLLs of both device groups are distributed. In contrast, a sharp increase in the difference in QFR gradient across the device is observed once LLL reaches more than 0.70 mm. IQR: interquartile range
Discussion
The major findings of the current substudy can be summarised as follows: 1) despite the in-stent LLL of the B-SES being significantly larger compared to the R-ZES, vessel QFR and QFR gradient across the device at nine-month follow-up (∆QFR FU ) in the B-SES arm were comparable to the R-ZES arm; 2) the in-stent LLLs of both groups were still within the range where difference in QFR gradient across the device between post procedure and follow-up (∆QFR FU -∆QFR POST ) has no functional repercussions.
3D-QCA-BASED FFR AND ANGIOGRAPHIC MEASUREMENT
The physiological assessment based on 3D-QCA (FFRQCA) has already been validated with sufficient accuracy and reproducibility in several studies comparing it to wire-derived FFR 10, 11, 15, 19, 20 . The diagnostic accuracy of the contrast-flow QFR for identifying an FFR of ≤0.80 was reported to be 86% (95% CI: 78% to 93%). This was comparable to the QFR value computed with hyperaemia (adenosine-flow QFR), which had a diagnostic accuracy of 87% (95% CI: 80% to 94%) 10 . In the FAVOR Pilot study and the WIFI II study, the diagnostic performance of QFR was compared to 2D angiographic measurement 10, 11 . The area under the receiver operating characteristic curve (AUC) of contrast-flow QFR to identify a wire-derived FFR of ≤0. . Tu et al showed the superiority of FFRQCA compared to % area stenosis derived from 3D angiography in terms of the predictive ability for a wirederived FFR value of ≤0.8 (AUC: 0.93 vs. 0.73) 15 .
In addition to the difference in the concept between QFR and conventional angiographic parameters, the less favourable predictive ability of conventional angiographic parameters for an FFR value of ≤0.8 is also ascribed to the difference of the region of interest (lesion versus vessel). In the current study, the number of lesions with QFR ≤0.8 was higher than that of angiographic binary restenosis (number of QFR ≤0.8: 9 [11.0%] in the B-SES group and 11 [11.0%] in the R-ZES group, number of binary restenosis: 3 [3.7%] in the B-SES group versus 3 [3.5%] in the R-ZES group) (Figure 4) . Nevertheless, QFR gradient across the device (∆QFR) is more comparable to the conventional angiographic parameter measured in the in-stent region of interest. However, as Figure 5 shows, the discrepancy was still observed between ∆QFR and binary restenosis, probably due to the fundamental difference between functional and anatomical assessments. Figure 6 shows a discrepancy between in-stent LLL (difference in angiographic minimum lumen diameter between post procedure and follow-up) and ∆QFR FU -∆QFR POST (difference in QFR gradient across the device between post procedure and follow-up). As Figure 6 shows, the difference of LLL within the low value range (<0.50 mm) was less significant from the physiological point of e 577 EuroIntervention 2018;14:e570-e579 PIONEER QFR substudy view. In this range of LLL, even if there is significant difference in LLL between two devices, the functionality of these devices does not differ. This suggests that LLL, a surrogate for in-stent neointimal growth, may not be directly correlated with the ischaemiadriven revascularisation, especially with low values of LLL.
CLINICAL IMPLICATIONS AND REGULATORY PERSPECTIVE
In a pooled data analysis of 11 stent trials, Pocock et al demonstrated that LLL and the probability of TLR were not correlated linearly but exponentially 3 . LLL with a high value range (>0.5-0.7 mm) was associated with an increased probability of TLR, whereas LLL in a low value range was not.
For a quarter of century, LLL has been used as a gold standard to assess the efficacy of coronary devices, not only in clinical studies but also for regulatory purposes 21 . However, this parameter may no longer reflect device efficacy in the current DES era, since the low values of LLL seem to have neither functional significance nor clinical implication 3 . In contrast, low LLL is potentially associated with safety issues such as delayed neointimal healing, evagination and malapposition, which in turn are strongly related with device thrombosis 22, 23 . In addition, the efficacy assessment based on the LLL derived from sixto nine-month angiography does not take into account the late "catch-up" phenomenon, which is potentially different among stent designs 24 . In contrast to durable polymer, bioresorbable polymer has the potential to reduce the risk of progressive neointimal hyperplasia in the late phase 25, 26 .
The optimal parameter validating stent performance should be related to physiological significance and clinical adverse events. Functional assessment based on 3D-QCA has the potential to validate stent performance more fundamentally with less invasiveness and a lower cost compared to wire-derived, although, to date, studies directly evaluating the impact of QFR on clinical outcomes have not been reported. The current post hoc analysis should be considered as hypothesis-generating only and should be prospectively and formally demonstrated.
Study limitations
The study was mainly designed for evaluating angiographic LLL. The physiological assessment based on QFR is a retrospective and non-pre-specified analysis. The number of data points was limited for drawing the regression curve that estimates the correlation between difference in QFR gradient across the device between post procedure and follow-up and in-stent LLL. The current QFR algorithm is based on the classic equation (∆P=FV+SV2) introduced by Young et al and simplified by Gould et al where F is the coefficient of pressure loss due to viscous friction in the stenotic segment (Poiseuille's law) and S is the coefficient of pressure loss due to flow separation at the diverging end of the stenosis (Bernoulli's law) 10, [27] [28] [29] . Using this equation, QFR is calculated based on lesion length, minimum lumen area and reference area derived from two angiographic views and volumetric flow of a single vessel calculated by using frame count 10 . This algorithm is simplified compared to the computational flow dynamics (CFD) using the Navier-Stokes equation.
Conclusions
In the PIONEER trial, the functional parameter (QFR) did not differ between B-SES and R-ZES at nine-month follow-up, despite a significant difference in in-stent LLL. In the current DES era, QFR may have the potential to serve as a novel type of assessment of device performance.
Impact on daily practice
In the PIONEER trial, although there was significant difference in nine-month in-stent late lumen loss between B-SES and R-ZES, the functional parameters of QFR did not differ between the two groups. The difference in late lumen loss within the very low value range did not have functional significance. In the current DES era, QFR is potentially a more adequate method for the assessment of device performance.
